Stokes Capital Advisors LLC Purchases 2,997 Shares of Zoetis Inc. $ZTS

Key Points

• Stokes Capital Advisors LLC increased its holdings in Zoetis Inc. by 10.6%, acquiring 2,997 shares, bringing its total to 31,289 shares valued at approximately $4.88 million.
• Analysts have issued mixed ratings on Zoetis, with five analysts rating it as a "Buy" and four as "Hold," while the consensus price target is $200.88.
• In its latest quarterly earnings, Zoetis reported earnings per share of $1.76, surpassing estimates, with revenues of $2.46 billion, reflecting a year-on-year growth of 4.2%.

Stokes Capital Advisors LLC grew its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 10.6% in the second quarter, according to its most recent filing with the SEC. The fund owned 31,289 shares of the company's stock after acquiring an additional 2,997 shares during the quarter. Stokes Capital Advisors LLC's holdings in Zoetis were worth $4,880,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Portside Wealth Group LLC boosted its position in shares of Zoetis by 24.7% during the 1st quarter. Portside Wealth Group LLC now owns 33,709 shares of the company's stock valued at $5,550,000 after acquiring an additional 6,672 shares during the last quarter. Tandem Investment Advisors Inc. boosted its position in shares of Zoetis by 100.3% during the 1st quarter. Tandem Investment Advisors Inc. now owns 395,626 shares of the company's stock valued at $65,140,000 after acquiring an additional 198,089 shares during the last quarter. Flagship Harbor Advisors LLC boosted its position in shares of Zoetis by 31.2% during the 1st quarter. Flagship Harbor Advisors LLC now owns 7,394 shares of the company's stock valued at $1,217,000 after acquiring an additional 1,760 shares during the last quarter. Horizon Financial Services LLC bought a new position in shares of Zoetis during the 1st quarter valued at approximately $380,000. Finally, Sage Rhino Capital LLC boosted its position in shares of Zoetis by 117.6% during the 1st quarter. Sage Rhino Capital LLC now owns 7,014 shares of the company's stock valued at $1,155,000 after acquiring an additional 3,791 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Leerink Partnrs downgraded Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Stifel Nicolaus downgraded Zoetis from a "buy" rating to a "hold" rating and lowered their price target for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Leerink Partners downgraded Zoetis from an "outperform" rating to a "market perform" rating and lowered their price target for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Piper Sandler raised their price target on Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Finally, Argus restated a "buy" rating and issued a $190.00 price target on shares of Zoetis in a research report on Tuesday, September 9th. Five equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, Zoetis has an average rating of "Moderate Buy" and a consensus price target of $200.88.

Zoetis Stock Performance

Shares of Zoetis stock opened at $147.44 on Wednesday. The firm has a market cap of $65.34 billion, a P/E ratio of 25.38, a P/E/G ratio of 2.35 and a beta of 0.89. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 12 month low of $139.70 and a 12 month high of $200.33. The stock's fifty day moving average price is $151.90 and its 200-day moving average price is $156.99.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. During the same quarter last year, the company earned $1.56 earnings per share. The firm's revenue for the quarter was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.